In a major health alert, California-based supplement company Boulla LLC has issued a voluntary nationwide recall of its products ZoomMax and ZapMax capsules. This recall follows testing conducted by the U.S. Food and Drug Administration (FDA), which found undeclared active ingredients—sildenafil and diclofenac. These ingredients are not listed on the packaging, posing serious health risks, especially to individuals on certain prescription medications or with pre-existing conditions. Sildenafil, commonly used to treat erectile dysfunction, can dangerously interact with nitrate-based drugs such as nitroglycerin, leading to potentially life-threatening drops in blood pressure. Adult males who use nitrate medications for heart issues are at the highest risk. Diclofenac, an NSAID used to control pain and inflammation, can increase the risk of severe cardiovascular events and gastrointestinal issues, such as bleeding and ulcers.

Affected Products:

• Lot Number: YZM240406

• Expiry Date: 04/05/27

• Packaging: 10-count blister packs

FDA Recommendations:

The FDA strongly recommends that consumers who have bought ZoomMax or ZapMax capsules stop using them immediately and consult their healthcare provider if they have experienced any adverse reactions.

Company Actions:

Boulla LLC is managing the return of these products via its online platform, including Amazon, and has informed distributors and customers.

Reporting Adverse Effects: Adverse reactions or quality concerns can be reported to the FDA’s MedWatch Adverse Event Reporting Program online at www.fda.gov/medwatch/report.htm.

This recall underscores the importance of regulatory vigilance and consumer awareness regarding dietary supplements. Always exercise caution and consult with healthcare professionals before taking new supplements, especially when combined with prescription medications.

Stay informed for updates on recalls and safety alerts.